Hengeler Mueller advises CELLINK on the acquisition of Scienion

Swedish CELLINK AB (publ) ("CELLINK") has entered into an agreement with the owners of Scienion AG ("Scienion") to acquire all shares for a purchase price on cash- and debt-free basis of EUR 80m. EUR 40m will be paid in 2,814,032 newly issued shares of series B in CELLINK and the reminder in cash. CELLINK is a global provider of technologies, products, and services to create, understand, and master cell and molecular biology. The Berlin based life science company Scienion is focusing on precision dispensing technologies.

Hengeler Mueller advised CELLINK on the transaction. The team was led by partner Hans-Jörg Ziegenhain and included partners Daniel Möritz (both Corporate/M&A), Markus Ernst (Tax) (all Munich) and Hendrik Bockenheimer (Employment, Frankfurt), counsel Benedikt Migdal, Patrick Wilkening (both IP/IT) and Susanne Koch (Public Law) (all Düsseldorf) as well as associates Jakub Lorys, Hanna Gotta, Thomas Weierer, Johannes Schmidt, Daniel Blagojevic (all Corporate/M&A), Tobias Schwab (Tax) (all Munich) and Marius Mayer (Employment, Frankfurt).